# Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

> **NCT02531308** · PHASE2 · TERMINATED · sponsor: **Rush University Medical Center** · enrollment: 5 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Metformin
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** pegfilgrastim

## Key facts

- **NCT ID:** NCT02531308
- **Lead sponsor:** Rush University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02531308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02531308, "Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02531308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*